Evidence map›Paper›PMID 21355967›Full record

Trial reportInternational journal of clinical practice2011

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.

R Pratley, M Nauck, T Bailey, E Montanya, R Cuddihy, S Filetti, A Garber, A B Thomsen, H Hartvig, M Davies and 1 more

Registry-linked trialOpen access · bronzeFull text readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of clinical practice, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00700817. Cited by 94 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 17 pooled it
26.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00700817 phase3completed

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes. A 26-week, Randomised, Open-label, Active Comparator, Three-armed, Parallel-group, Multi-centre, Multinational Trial With a 52-week Extension

Ran2008Enrolled665Registered outcomes75Posted comparisons6ConditionsDiabetes, Diabetes Mellitus, Type 2Armsliraglutide, Metformin, Sitagliptin
PMID 21883806PMID 23010561PMID 21883438PMID 26936426PMID 22851600PMID 22193143PMID 25504028PMID 23186975PMID 21309842PMID 20417856PMID 22834986PMID 22862847other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 17 syntheses or guidelines pooled it, 248 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies.The European journal of health economics : HEPAC : health economics in prevention and care · 2017
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. Trial
  20. Trial

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 6 countries.

R PratleyDiabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, VT 04556, USA. richard.pratley@uvm.edu
M Nauck
T Bailey
E Montanya
R Cuddihy
S Filetti
A Garber
A B Thomsen
H Hartvig
M Davies
1860-LIRA-DPP-4 Study Group
Novo Nordisk (Denmark) · DKAMCR Institute · USBaylor College of Medicine · USDiabeteszentrum Bad Lauterberg · DEInstitut d'Investigació Biomédica de Bellvitge · ESSapienza University of Rome · ITUniversity of Leicester · GBUniversity of Vermont · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe aim of this study was to compare the efficacy and safety of once-daily human glucagon-like peptide-1 analogue liraglutide with dipeptidyl peptidase-4 inhibitor sitagliptin, each added to metformin, over 52 weeks in individuals with type 2 diabetes.

methodsIn an open-label, parallel-group trial, metformin-treated participants were randomised to liraglutide 1.2 mg/day (n=225), liraglutide 1.8 mg/day (n=221) or sitagliptin 100 mg/day (n=219) for 26 weeks (main phase). Participants continued the same treatment in a 26-week extension.

resultsLiraglutide (1.2 or 1.8 mg) was superior to sitagliptin for reducing HbA(1c) from baseline (8.4-8.5%) to 52 weeks: -1.29% and -1.51% vs. -0.88% respectively. Estimated mean treatment differences between liraglutide and sitagliptin were as follows: -0.40% (95% confidence interval -0.59 to -0.22) for 1.2 mg and -0.63% (-0.81 to -0.44) for 1.8 mg (both p<0.0001). Weight loss was greater with liraglutide 1.2 mg (-2.78 kg) and 1.8 mg (-3.68 kg) than sitagliptin (-1.16 kg) (both p<0.0001). Diabetes Treatment Satisfaction Questionnaire scores increased significantly more with liraglutide 1.8 mg than with sitagliptin (p=0.03). Proportions of participants reporting adverse events were generally comparable; minor hypoglycaemia was 8.1%, 8.3% and 6.4% for liraglutide 1.2 mg, 1.8 mg and sitagliptin respectively. Gastrointestinal side effects, mainly nausea, initially occurred more frequently with liraglutide, but declined after several weeks.

conclusionLiraglutide provides greater sustained glycaemic control and body weight reduction over 52 weeks. Treatment satisfaction was significantly greater with 1.8 mg liraglutide, similar to 26-week results. The safety profiles of liraglutide and sitagliptin are consistent with previous reports.

Indexed as

AgedBlood GlucoseDiabetes Mellitus, Type 2Drug Therapy, CombinationFastingFemaleGlucagon-Like Peptide 1Glycated HemoglobinHumansHypoglycemic AgentsLiraglutideMaleMetforminMiddle AgedPyrazinesSitagliptin PhosphateBlood GlucoseGlucagon-Like Peptide 1Glycated HemoglobinHypoglycemic AgentsLiraglutideMetforminPyrazinesSitagliptin PhosphateTriazoles

Identifiers

PMID21355967
PMCPMC3085127
OpenAlexW1559082056

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.